Clinical Trial Search

Primary: Change From Baseline in Mean Monthly Migraine Days (MMD) Over Months 4, 5, and 6 of the Double-blind Treatment Period — -1.98; -3.60 migraine days / month — p=<0.001

Primary: Capsaicin Sensitivity — 2.47 score on a scale

Primary: Change in Global Spontaneous Pain Intensity of Target Hand — -20; -11.3 mm — p=0.016

Primary: Changes in Brain Activity (fMRI) as Assessed by Variance in BOLD Signal — 15.65; 18.06; 23.39; 8.93 variance in BOLD signal — p=.006

Primary: Change in Accelerometer Measured Moderate to Vigorous PA (MVPA) by the Actigraph GT3X+ — 10; 0; 36; 28 minutes/week — p=0.24

Primary: Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168) — 1.961; 1.089; 2.734 Angioedema event rate per…

Primary: CGI-I — 2 units on a scale

Primary: Number of Participants With Adverse Events (AEs) — 32; 70 Participants

Primary: Acute Haemodynamic Response to Dual Left Ventricular Pacing — 3.7 % difference — p=<0.05

Primary: Number of Samples Collected for the Identification of Biomarkers for Early Evaluation of Risk of Developing Hepatosplenic T-cell Lymphoma (HSTCL)

Primary: Capsaicin Sensitivity — 2.05 score on a scale

Primary: Change in Balance During a Dynamic Task Using Force Plates. — 32.4; 18.1; 10 percentage of change

Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120

Primary: West Haven-Yale Multidimensional Pain Inventory - Interference (WHYMPI-I) to Assess Change at Follow up — 3.43; 3.10 units on a scale — p=.486

Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC[0 to Inf]) for GSK3640254-Part 1 — 36.94; 36.88 Hours*microgram per milliliter